ProMIS Neurosciences Inc PMN

Management Failure

[TopBroker]

It is hard to see a Company with good science and poor management. The only way you can get this back into the limelight is ask your CEO and Board Chairman to
step aside and let a qualified party take over the reigns and pilot this to the markets attention. James Kupiek with his credits from big Pharma is an obvious choice.

[farmerjane]

Not sure this will help, they have changed management a couple times, not getting anything takers on there science. Nothing in clinical trials.

[M101]

Agree that management shuffle may not help as I believe it will be the technology which sells itself, but it's just not ready yet.  Of course I would never expect to hear this from Gene or Elliot. What would help though is management taking a serious part of their package in options instead of cash. This would help not just with cash flow but with the market's perception of inherent

[G1945V]

TP, .... best to wait out Aducanumab to gain acceptance by FDA to prove that the beta-amyloid theory of Alzheimer's disease is still a viable working hypothesis, paving the way for a more targeted therapies PMN has to offer. Perhaps, this is what management is waiting for.    jmo G1945V 

[farmerjane]

And if Aducanumab doesn't gain acceptance ? Either way Biogen's drug has shown promising results hard to believe after billions have been spent that pharma isn't willing to spend a few million and advance PM310 into the clinic? Not lining up!!!!

[Mole101]

ProMIS Summary • Unique proprietary technology platform – rapid, cost-effective, differentiated • Strategic portfolio in Alzheimer’s based on unique platform – Detect – Treat – Prevent • PMN310 scientifically superior to likely “first in class” therapy Biogen’s aducanumab, PMN310 selective for toxic oligomers, stronger binding • Biogen granted Priority Review by the FDA, potential Q1

[Silencio13]

Hard to believe you're still posting here.

[G1945V]

"And if Aducanumab doesn't gain acceptance." then, in my opinion, the beta-amyloid hypothesis may very well end up dead in the water. PMN will have a much bigger hill to climb, sourcing badly needed funds to prove their more targeted toxic form of amyloid-beta with PMN310.     I believe that Aducanumab will succeed, which will pave the way for

[Annayya]

The PDUFA date is March 7, 2021 for FDA Approval of Aducanumab. It's not an extremely long wait but PMN might need a couple PPs by then. The only way they can increase SP value in the mean time is through the covid test with neutralizing antibodies identification success news and possible revenue in Q4 2020, which they talked about in the previous corporate update. However, it seems covid